MarketCap
Facebook
X
Telegram
NextGen Healthcare Balance Sheet 2023-2008 | NXGN
Brief overview of NextGen Healthcare's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2019 and 2023.
Total assets increased by +68.2%, from $532.9 million to $896.1 million. A CAGR near 13.9% points to substantial expansion.
Liability growth of +215.8% exceeded asset growth of +68.2%, increasing reliance on outside funding.
The equity ratio is 44.7% versus 70.5% five periods ago. Capitalization remains workable.
Net debt to equity stands at 0.43x; the current burden does not look excessive.
Cash represents 11% of assets versus 6.2% initially, showing how the immediate liquidity reserve changed.
Retained earnings reached $127.6 million, changing +14.3% over the period. A positive accumulated result supports equity.
Balance sheet takeaway
NextGen Healthcare retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet NextGen Healthcare
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
172 M | -39.8 M | -42.1 M | -88.6 M | -22.1 M | 8.16 M | -22.7 M | 77.8 M | -119 M | -103 M | -106 M | -134 M | -117 M | - | - | - |
Long Term Debt |
267 M | 11.9 M | 18.5 M | 38.8 M | 11 M | 37 M | 15 M | 105 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.83 M | 8.09 M | 12.7 M | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 176 M | 28.7 M | 57.8 M | 39.5 M | 123 M | 21.9 M | 26.1 M | 8.98 M | 15.7 M | 17.4 M | - | - | - |
Total Current Liabilities |
198 M | 181 M | 181 M | 143 M | 128 M | 135 M | 129 M | 138 M | 155 M | 127 M | 127 M | 129 M | 137 M | 101 M | - | - |
Total Liabilities |
496 M | 205 M | 213 M | 320 M | 157 M | 192 M | 168 M | 261 M | 177 M | 156 M | 136 M | 145 M | 154 M | 122 M | - | - |
Deferred Revenue |
61.6 M | 61.3 M | 52.9 M | 56.8 M | 56 M | 54.1 M | 52.4 M | 57.9 M | 66.3 M | 71.1 M | 65.2 M | 83.1 M | 76.7 M | 64.1 M | - | - |
Retained Earnings |
128 M | 130 M | 129 M | 119 M | 112 M | 78.7 M | 76.2 M | 58 M | 84.5 M | 99.9 M | 127 M | 126 M | 91.1 M | 65.7 M | - | - |
Total Assets |
896 M | 628 M | 644 M | 720 M | 533 M | 516 M | 473 M | 531 M | 461 M | 451 M | 443 M | 440 M | 379 M | 310 M | - | - |
Cash and Cash Equivalents |
98.7 M | 59.8 M | 73.3 M | 138 M | 33.1 M | 28.8 M | 37.7 M | 27.2 M | 119 M | 103 M | 106 M | 134 M | 134 M | 117 M | 70.2 M | 59 M |
Book Value |
400 M | 423 M | 432 M | 400 M | 376 M | 323 M | 305 M | 269 M | 284 M | 295 M | 307 M | 295 M | 225 M | 188 M | - | - |
Total Shareholders Equity |
400 M | 423 M | 432 M | 400 M | 376 M | 323 M | 305 M | 269 M | 284 M | 295 M | 307 M | 295 M | 225 M | 188 M | 156 M | 114 M |
All numbers in USD currency
Quarterly Balance Sheet NextGen Healthcare
| 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
268 M | 267 M | 267 M | 5.15 M | 9.79 M | - | 12.8 M | 14.6 M | 16.4 M | 12.8 M | 29.3 M | 36.4 M | 18.5 M | 29.3 M | 39.3 M | 41.6 M | 36.1 M | 39.3 M | 41.6 M | 44.3 M | - | - | - | - | - | - | - | - | - | - | - | - | 105 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
434 M | 458 M | 453 M | 185 M | 179 M | - | 194 M | 200 M | 186 M | 194 M | 230 M | 253 M | 213 M | 230 M | 223 M | 182 M | 366 M | 223 M | 165 M | 180 M | 157 M | 165 M | 180 M | 198 M | 198 M | 171 M | 171 M | 189 M | 176 M | 165 M | 165 M | 193 M | 235 M | 149 M | 149 M | 149 M | 161 M | 157 M | 157 M | 155 M | 151 M | 148 M | 148 M | 147 M | 135 M | 119 M | 119 M | 144 M | 154 M | 159 M | 159 M | 148 M | 150 M | 142 M | 127 M | 126 M |
Deferred Revenue |
45.9 M | 48.3 M | 62.6 M | 62.5 M | 63.1 M | - | 54.9 M | 53.5 M | 52.3 M | 54.9 M | 48.7 M | 48.4 M | 52.9 M | 48.7 M | 52.9 M | 54.1 M | 51.2 M | 52.9 M | 50.4 M | 50 M | 56 M | 50.4 M | 50 M | 52.2 M | 52.2 M | 52.8 M | 52.8 M | 52.3 M | 51.5 M | 49.8 M | 49.8 M | 52.3 M | 54.4 M | 55.1 M | 55.1 M | 57.7 M | 61.9 M | 67.8 M | 67.8 M | 69.6 M | 70.7 M | 72.7 M | 72.7 M | 66.6 M | 62.7 M | 63 M | 63 M | 68 M | 70.7 M | 90.6 M | 90.6 M | 83.3 M | 80 M | 71.9 M | 65.7 M | 63.6 M |
Retained Earnings |
139 M | 134 M | 153 M | 145 M | 131 M | - | 130 M | 125 M | 131 M | 130 M | 129 M | 129 M | 129 M | 129 M | 123 M | 119 M | 118 M | 123 M | 108 M | 103 M | 112 M | 108 M | 103 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 88.2 M | 80.2 M | 71.8 M | 71.8 M | 61.3 M | 57.3 M | 74.3 M | 74.3 M | 77.7 M | 80.1 M | 84.4 M | 84.4 M | 88.5 M | 94.4 M | 105 M | 105 M | 129 M | 129 M | 141 M | 141 M | 136 M | 131 M | 121 M | 121 M | 110 M | 99.9 M | 82.7 M | 73.9 M | 69.1 M |
Total Assets |
858 M | 868 M | 871 M | 627 M | 608 M | - | 605 M | 636 M | 625 M | 605 M | 656 M | 672 M | 644 M | 656 M | 623 M | 573 M | 770 M | 623 M | 531 M | 536 M | 533 M | 531 M | 536 M | 535 M | 535 M | 501 M | 501 M | 514 M | 490 M | 463 M | 463 M | 479 M | 505 M | 433 M | 433 M | 436 M | 441 M | 439 M | 439 M | 440 M | 442 M | 448 M | 448 M | 467 M | 445 M | 440 M | 440 M | 457 M | 460 M | 442 M | 442 M | 417 M | 400 M | 353 M | 328 M | 320 M |
Cash and Cash Equivalents |
53.9 M | 70.3 M | 242 M | 70.7 M | 40.4 M | - | 49.4 M | 75.3 M | 63 M | 49.4 M | 89.5 M | 103 M | 73.3 M | 89.5 M | 26.8 M | 42.9 M | 192 M | 26.8 M | 30.1 M | 32.4 M | 33.1 M | 30.1 M | 32.4 M | 26.5 M | 26.5 M | 23.4 M | 23.4 M | 26.6 M | 23.3 M | 24 M | 24 M | 26.2 M | 26.3 M | 92.6 M | 92.6 M | 98.6 M | 105 M | 114 M | 114 M | 115 M | 108 M | 82.1 M | 82.1 M | 72.8 M | 118 M | 102 M | 102 M | 117 M | 130 M | 129 M | 129 M | 126 M | 124 M | 118 M | 107 M | 93.2 M |
Book Value |
423 M | 411 M | 418 M | 442 M | 429 M | - | 411 M | 435 M | 439 M | 411 M | 426 M | 420 M | 432 M | 426 M | 400 M | 391 M | 404 M | 400 M | 365 M | 355 M | 376 M | 365 M | 355 M | 337 M | 337 M | 331 M | 331 M | 326 M | 314 M | 298 M | 298 M | 285 M | 270 M | 285 M | 285 M | 287 M | 280 M | 283 M | 283 M | 285 M | 291 M | 300 M | 300 M | 321 M | 310 M | 321 M | 321 M | 312 M | 307 M | 282 M | 282 M | 269 M | 251 M | 212 M | 201 M | 194 M |
Total Shareholders Equity |
423 M | 411 M | 418 M | 442 M | 429 M | - | 411 M | 435 M | 439 M | 411 M | 426 M | 420 M | 439 M | 426 M | 400 M | 391 M | 404 M | 400 M | 365 M | 355 M | 381 M | 365 M | 365 M | 355 M | 337 M | 331 M | 331 M | 326 M | 314 M | 298 M | 298 M | 285 M | 270 M | 285 M | 285 M | 287 M | 280 M | 283 M | 283 M | 285 M | 291 M | 300 M | 300 M | 321 M | 310 M | 321 M | 321 M | 312 M | 307 M | 282 M | 282 M | 269 M | 251 M | 212 M | 201 M | 194 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of NextGen Healthcare, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Teladoc Health
TDOC
|
$ 6.26 | 0.24 % | $ 1.1 B |  USA |
 |
10x Genomics
TXG
|
$ 65.6 | 4.71 % | $ 8.18 B | USA |
 |
Veeva Systems
VEEV
|
$ 264.84 | 1.3 % | $ 43.3 B | USA |
 |
Zhongchao
ZCMD
|
$ 0.85 | 0.29 % | $ 2.91 M |  China |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
American Well Corporation
AMWL
|
$ 13.34 | 2.69 % | $ 214 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
$ 4.22 | 1.41 % | $ 482 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.52 | 1.15 % | $ 1.25 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.7 | 0.59 % | $ 119 M | USA |
 |
HealthEquity
HQY
|
$ 93.36 | 0.24 % | $ 8.04 B | USA |
 |
HealthStream
HSTM
|
$ 28.72 | 1.78 % | $ 862 M | USA |
 |
So-Young International
SY
|
$ 2.65 | 0.18 % | $ 206 M | China |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Omnicell
OMCL
|
$ 33.88 | 0.32 % | $ 1.56 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.6 | 1.74 % | $ 141 M | USA |
 |
Progyny
PGNY
|
$ 27.15 | 4.66 % | $ 2.31 B | USA |
 |
Phreesia
PHR
|
$ 10.22 | 0.76 % | $ 611 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
$ 20.03 | 0.2 % | $ 1.47 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |